THE CONCEPT OF VALUE-BASED HEALTHCARE: OPPORTUNITIES FOR DRUG PRICING
- Authors: Lemeshko V.A.1,2, Musina N.Z.1,3
-
Affiliations:
- Center of Healthcare Expertise and Quality Control, Ministry of Health of the Russian Federation
- I.M. Sechenov First Moscow State Medical University (Sechenov University)
- Saint Petersburg State Chemical Pharmaceutical University
- Issue: Vol 69, No 5 (2020)
- Pages: 37-42
- Section: Articles
- URL: https://journals.eco-vector.com/0367-3014/article/view/113356
- DOI: https://doi.org/10.29296/25419218-2020-05-06
- ID: 113356
Cite item
Abstract
Full Text
About the authors
Valeriya Aleksandrovna Lemeshko
Center of Healthcare Expertise and Quality Control, Ministry of Health of the Russian Federation; I.M. Sechenov First Moscow State Medical University (Sechenov University)
Email: lera.lemeschko@yandex.ru
Head Deputy of the Department of Methodological Support of Comprehensive HTA; post graduate student of the Department of Pharmacology 10, Khokhlovsky Lane, Build. 5, Moscow 109028, Russian Federation; 8, Trubetskaya St., Build. 2, Moscow119991, Russian Federation
Nuriya Zagitovna Musina
Center of Healthcare Expertise and Quality Control, Ministry of Health of the Russian Federation; Saint Petersburg State Chemical Pharmaceutical University
Email: nuriyamusina@gmail.com
Associate Professor of the Department of Management and Farmacoeconomics; Head of the Development and Communications Department 10, Khokhlovsky Lane, Build. 5, Moscow 109028, Russian Federation; 14, Prof. Popov St., Saint Petersburg 197376, Russian Federation
References
- Porter M.E., Lee T.H. From Volume to Value in Health Care: The Work Begins. JAMA. 2016; 316 (10): 1047-8. doi: 10.1001/jama.2016.11698
- Garrison L.P., Towse A. Value-Based Pricing and Reimbursement in Personalised Healthcare: Introduction to the Basic Health Economics. J. Pers. Med., 2017; 7 (3): 10. doi: 10.3390/jpm7030010
- Garner S., Rintoul A., Hill S.R. Value-Based Pricing: L'Enfant Terrible?. Pharmacoeconomics, 2018; 36 (1): 5-6. doi: 10.1007/s40273-017-0567-4
- Moreno S.G., Ray J.A. The value of innovation under value-based pricing. J. Mark. Access. Health Policy. 2016; 4. doi: 10.3402/jmahp.v4.30754.
- Jommi C., Armeni P., Costa F. et al. Implementation of value-based pricing for medicines. Clinical therapeutics, 2019; 42 (1): 15-24. doi: 10.1016/j.clinthera.2019.11.006
- Kanavos P., Manning J., Taylor D. et al. Implementing value-based pricing for pharmaceuticals in the UK. London: 2020 health. 2010.
- Keckley P.H., Snyder G. Value Based Pricing for Pharmaceuticals, Implications of the Shift from Volume to Value. Deloitte Center for Health Solutions, 2012.
- Sussex J., Towse A., Devlin N. Operationalizing value-based pricing of medicines: a taxonomy of approaches. Pharmacoeconomics. 2013; 31: 1-10. doi: 10.1007/s40273-012-0001-x
- Net Monetary Benefit [online]. York; York Health Economics Consortium; 2016. [Electronic resource]. Access mode: https://yhec.co.uk/glossary/net-monetary-benefit (circulation date: 15.06.2020).
- Paulden M. Recent amendments to NICE's value-based assessment of health technologies: implicitly inequitable? Expert.Rev. Pharmacoecon. Outcomes. Res., 2017; 17 (3): 239-42. doi: 10.1080/14737167.2017.1330152
- National Institute of Health and Clinical Excellence. Changes to NICE drug appraisals: what you need to know. [Electronic resource]. Access mode: https://www.nice.org.uk/ news/feature/changes-to-nice-drug-appraisals-what-you-need-to-know
- National Institute of Health and Clinical Excellence. Centre for health technology evaluation. Consultation Paper Value Based Assessment of Health Technologies. [Electronic resource]. Access mode: https://www.nice.org.uk/Media/Default/ About/what-we-do/NIC
- Омельяновский В.В., Никитина А.В., Лемешко В.А., Хачатрян Г.Р. Лекарственное обеспечение и оценка технологий здравоохранения во Франции. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2020; 13 (1): 71-83. doi: 10.17749/2070
- Wenzl M., Paris V. Pharmaceutical reimbursement and pricing in Germany. 2018.
- Rahmenvereinbarungnach § 130b Abs. 9 SGB V. [Electronic resource]. Access mode: https://www.gkv-spitzenver-band.de/media/dokumente/krankenversicherung_1/arzneimittel/ rahmenvertraege/pharmazeutische_unternehmer/ Rahmenvereinbarung_130b_Abs9 SGB_V_2016.pdf
- Горкавенко Ф.В., Омельяновский В.В., Безденежных Т.П., Хачатрян Г.Р. Оценка технологий здравоохранения и система лекарственного возмещения в Италии. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2019; 12 (2): 156-64. doi: 10.17749/2070-4909.2019.12.2.156-164